From the OP, and all through the post, I am surprised no-one has mentioned some of the theorised effects of Gingivalis P., the bacteria involved in periodontal disease.
For e.g. there are early stage theories that Gingivalis P. is potentially involved in Alzheimers disease.
This would not be the reason for the investment given the stage of the science but just pulling the narrative toward some science and clinical needs.
From the OP, and all through the post, I am surprised no-one has...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$300.26 |
Change
-1.400(0.46%) |
Mkt cap ! $145.3B | |||
| Open | High | Low | Value | Volume |
| $303.31 | $303.47 | $299.56 | $148.6M | 498.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 276 | $300.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $300.34 | 1250 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |